Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
Executive Summary
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.
You may also be interested in...
Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships
Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.
Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer
Celgene's fourth quarter earnings report delivered no revenue surprises, but the company noted its pipeline progress and insisted that business development is the main priority for its $12bn in cash as it looks to bring in new assets that can boost post-Revlimid growth.
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.